Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
JN Diehl, PS Hibshman, I Ozkan-Dagliyan… - Advances in Cancer …, 2022 - Elsevier
Mutational activation of the KRAS oncogene is found in~ 95% of pancreatic ductal
adenocarcinoma (PDAC), the major form of pancreatic cancer. With substantial experimental
evidence that continued aberrant KRAS function is essential for the maintenance of PDAC
tumorigenic growth, the National Cancer Institute has identified the development of effective
anti-KRAS therapies as one of four major initiatives for pancreatic cancer research. The
recent clinical success in the development of an anti-KRAS therapy targeting one specific …
adenocarcinoma (PDAC), the major form of pancreatic cancer. With substantial experimental
evidence that continued aberrant KRAS function is essential for the maintenance of PDAC
tumorigenic growth, the National Cancer Institute has identified the development of effective
anti-KRAS therapies as one of four major initiatives for pancreatic cancer research. The
recent clinical success in the development of an anti-KRAS therapy targeting one specific …